Tags

Type your tag names separated by a space and hit enter

Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.
Vaccine. 2007 Mar 22; 25(13):2451-7.V

Abstract

The long-term immunogenicity and vaccine efficacy (VE) of a 9-valent conjugate pneumococcal vaccine was studied in HIV infected and HIV non-infected children. VE against vaccine-serotype invasive pneumococcal disease following 6.16 years of follow-up persisted in HIV non-infected children (77.8%; 95% CI 34.4-92.5 compared to 83% after 2.3 years of follow-up), and declined from 65% to 38.8% (95% CI -7.8 to 65.2) in HIV infected children. HIV non-infected vaccinees had equal (serotypes 4, 6B, 14, 19F) or greater (serotypes 9V, 18C, 23F) proportions of serotype-specific antibody concentrations of > or =0.2microg/ml to vaccine-serotypes analyzed compared to HIV infected vaccinees at 5.3 years of age.

Authors+Show Affiliations

University of the Witwatersrand/Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, South Africa. madhis@hivas.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17023095

Citation

Madhi, Shabir A., et al. "Long-term Immunogenicity and Efficacy of a 9-valent Conjugate Pneumococcal Vaccine in Human Immunodeficient Virus Infected and Non-infected Children in the Absence of a Booster Dose of Vaccine." Vaccine, vol. 25, no. 13, 2007, pp. 2451-7.
Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine. 2007;25(13):2451-7.
Madhi, S. A., Adrian, P., Kuwanda, L., Jassat, W., Jones, S., Little, T., Soininen, A., Cutland, C., & Klugman, K. P. (2007). Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine, 25(13), 2451-7.
Madhi SA, et al. Long-term Immunogenicity and Efficacy of a 9-valent Conjugate Pneumococcal Vaccine in Human Immunodeficient Virus Infected and Non-infected Children in the Absence of a Booster Dose of Vaccine. Vaccine. 2007 Mar 22;25(13):2451-7. PubMed PMID: 17023095.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. AU - Madhi,Shabir A, AU - Adrian,Peter, AU - Kuwanda,Locadiah, AU - Jassat,Wasilla, AU - Jones,Stephanie, AU - Little,Tessa, AU - Soininen,Anu, AU - Cutland,Clare, AU - Klugman,Keith P, Y1 - 2006/09/20/ PY - 2006/10/7/pubmed PY - 2007/9/15/medline PY - 2006/10/7/entrez SP - 2451 EP - 7 JF - Vaccine JO - Vaccine VL - 25 IS - 13 N2 - The long-term immunogenicity and vaccine efficacy (VE) of a 9-valent conjugate pneumococcal vaccine was studied in HIV infected and HIV non-infected children. VE against vaccine-serotype invasive pneumococcal disease following 6.16 years of follow-up persisted in HIV non-infected children (77.8%; 95% CI 34.4-92.5 compared to 83% after 2.3 years of follow-up), and declined from 65% to 38.8% (95% CI -7.8 to 65.2) in HIV infected children. HIV non-infected vaccinees had equal (serotypes 4, 6B, 14, 19F) or greater (serotypes 9V, 18C, 23F) proportions of serotype-specific antibody concentrations of > or =0.2microg/ml to vaccine-serotypes analyzed compared to HIV infected vaccinees at 5.3 years of age. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/17023095/Long_term_immunogenicity_and_efficacy_of_a_9_valent_conjugate_pneumococcal_vaccine_in_human_immunodeficient_virus_infected_and_non_infected_children_in_the_absence_of_a_booster_dose_of_vaccine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(06)01021-8 DB - PRIME DP - Unbound Medicine ER -